Collegium Pharma (NASDAQ: COLL) reported Q3 EPS of $1.61, $0.04 better than the analyst estimate of $1.57. Revenue for the quarter came in at $159.3 million versus the consensus estimate of $156.88 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.